Table 2.
Characteristics of the randomized placebo-controlled trials considered for the guideline in chronic migraine
| Study | Study phase | Treatment regimen | Duration of treatment | Participants (n) | Women (%) | Age range (years) |
Definition of chronic migraine | Preventive treatment (% using) |
Exclusion by preventive failure (n. of drugs/ categories) |
|---|---|---|---|---|---|---|---|---|---|
| Erenumab | |||||||||
| Tepper, 2017 [45] | II |
70 mg monthly sc 140 mg monthly sc |
3 months | 667 | 79–87 | 18–65 | ICHD-3, beta version | Not allowed | > 3 |
| Fremanezumab | |||||||||
| Bigal, 2015 [26] | II | 225 mg monthly sc (675 mg ld) | 3 months | 264 | 85–86 | 18–65 | ICHD-3, beta version | 38–43 | > 3 |
| HALO CM [41] | III |
225 mg monthly sc (675 mg ld) 675 mg quarterly sc |
3 months | 1130 | 87–88 | 18–70 | ICHD-3, beta version | 20–22 | ≥2 |
| Galcanezumab | |||||||||
| REGAIN [31] | III |
120 mg monthly sc (240 mg ld) 240 mg monthly sc |
3 months | 1117 | 82–87 | 18–65 | ICHD-3, beta version (required at least 1 headache-free day per month) | 13–16 | > 2 |
sc: subcutaneous; ld loading dose